Pfizer Inc. closed $4.92 short of its 52-week high ($31.54), which the company reached on July 30th.

The German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...

We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...